Navigation Links
Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
Date:9/27/2010

NEW YORK, Sept. 27 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the JMP Securities Healthcare Conference, being held at the New York Palace Hotel in New York City.  Mr. Bentsur's presentation is scheduled to take place tomorrow, Tuesday, September 28, 2010, at 1:00 p.m.

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of each webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing Zerenex™ (ferric citrate), an oral, iron-based compo
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
3. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
4. Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
5. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
6. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
7. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
9. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
10. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
11. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... SAN ANTONIO, Texas , Sept. 18, 2014  Casen ... vessels, skin and muscles to harden.  His case is one ... (GVM) in the world.  The only hospital in ... few in the world, offering treatment with the dual wave-length ... in San Antonio . Using a laser ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... companies. Competition for innovation, increasing clinical development costs, ... with the fast-changing environment are important factors driving ... and clinical trial costs continue to rise due ... Studies conducted by industry think tanks suggest ...
(Date:9/18/2014)... NORTHVALE, N.J. , Sept. 18, 2014 /PRNewswire/ ... Gianluca DeNovi , Ph.D. to its corporate ... DeNovi is an instructor at the Harvard Medical ... Bio-Medico of Rome.  He received his Masters degree ... and Control Systems from the University of Bologna. After ...
Breaking Medicine Technology:Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3
(Date:9/18/2014)... 18, 2014 (HealthDay News) -- Daily supplements of selenium ... the development of age-related cataracts among men, a new ... one or both could help prevent cataracts. To investigate ... and Harvard Medical School in Boston, and his colleagues ... and vitamin E. The trial was initially designed to ...
(Date:9/18/2014)... TayganPoint Consulting Group, a leading strategic ... co-founder John Cassimatis was named as one of ... recognizing the region’s top healthcare and life science ... the year. , The Innovation Awards celebrate companies ... to shape the medical industry in Greater Philadelphia ...
(Date:9/18/2014)... Stealth Health Revolution co-founders, Montel ... Frank Davis, founder of Food for Health International ... to announce the new recipe book, "The Simple ... meals using Activz whole-food powders." The Simple ... the Stealth Health Revolution mission to ...
(Date:9/18/2014)... companies can expect to pay higher employee contributions for ... human resource officers about the impact of the Patient ... or Obamacare) conducted by the Darla Moore School of ... May/June. , Patrick Wright, a professor in strategic human ... Chief HR Officers. The survey is distributed to more ...
(Date:9/18/2014)... develop tools that would allow them to clearly view ... neuron fires to the resulting behavior in a whole ... to develop a range of new tools to study ... tool that provides a new way of mapping neural ... between Viviana Gradinaru (BS ,05), assistant professor of biology ...
Breaking Medicine News(10 mins):Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 3Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 2Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 3Health News:Sensing neuronal activity with light 2Health News:Sensing neuronal activity with light 3Health News:Sensing neuronal activity with light 4Health News:Sensing neuronal activity with light 5
... May 13th at Long Beach Veterans Administration Hospital, ... West Hills/Northridge,Veterans Administration will honor Dr. Richard Merkin, ... the health of American,war veterans. The VA, in ... a clinical research study aimed at,examining diabetic ulcers ...
... Colo., April 24 Heska Corporation,(Nasdaq: HSKA ) announces the following Webcast:, ... Earnings Conference Call on the Web, ... (click on the Q1 2008 Earnings Call link on ... Live over the Internet -- Simply log on to the web at the address ...
... Members, Elect New Member to Board, Reject ... Stockholder Proposals - ... -, MADISON, N.J., April 24 At today,s Annual,Meeting of Stockholders ... 12 current members of the Company,s Board of,Directors and elected nominee Michael ...
... David B. Snow,Jr., chairman & chief executive officer ... scheduled to address the Morgan Stanley Global Healthcare,Unplugged Conference ... The presentation at the Ritz-Carlton, Key Biscayne, will begin ... financial officer, is also,scheduled to attend., The presentation ...
... New Call Center, WASHINGTON, April 24 On ... contacting nearly 570,000,recent combat veterans to ensure they know ... reach out and touch every veteran of Operation Enduring,Freedom ... are here for them,",said Dr. James B. Peake, Secretary ...
... concepts through abstract cases more likely to retain knowledge, ... The use of "real-world" concrete examples doesn,t help students ... that challenges the widespread use of this approach in ... who learned a mathematical concept with concrete examples couldn,t ...
Cached Medicine News:Health News:Veterans Honor Dr. Richard Merkin During Research Week 2Health News:Webcast Alert: Heska Announces First Quarter 2008 Earnings Conference Call Webcast 2Health News:Wyeth Holds Annual Meeting of Stockholders 2Health News:Wyeth Holds Annual Meeting of Stockholders 3Health News:Wyeth Holds Annual Meeting of Stockholders 4Health News:Medco CEO to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2Health News:VA Calling All Recent Combat Vets 2Health News:'Real World' Examples Don't Make Math Any Easier 2
Cross action, round handle, maximum opening 2.8 mm....
Irrigating nucleus chopper, tip angled 30 to side wedge shaped inferior edge with blunt tip and front notch for engaging iris end opening, 19 gauge. For use in the right hand....
Irrigating nucleus chopper, wedge-shaped inferior edge with, blunt tip, 0.6 mm dual sideports, 20 gauge....
Irrigating nucleus chopper, semi-sharp, wedge shaped inferior edge with a pointed tip, dual sideports, 20 gauge. For Phakonit cataract surgery....
Medicine Products: